Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on October 14, 2025. The report addresses a corporate governance event regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
On October 14, 2025, the Company filed Certificates of Elimination with the Delaware Secretary of State. This action effectively eliminated the Series B convertible preferred stock and Series C convertible preferred stock from the Company's Certificate of Incorporation. All matters set forth in the Certificates of Designations for these preferred stock classes were removed effective upon filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The document is strictly procedural regarding the elimination of specific preferred stock classes.
Investor Verification Checklist
- Verify the status of the Series B and Series C convertible preferred stock to confirm they are no longer outstanding.
- Review the attached Exhibits 3.1 and 3.2 (Certificates of Elimination) for specific terms regarding the elimination.
- Check subsequent filings for any impact this capital structure change may have on the company's authorized share count or future financing capabilities.